Major review maps the expanded endocannabinoid system and its therapeutic potential across neurological diseases
A comprehensive Nature Reviews Neurology article describes the expanded "endocannabinoidome" and its clinical relevance to neurological disorders from epilepsy and MS to Parkinson's and Alzheimer's disease.
Quick Facts
What This Study Found
Beyond the classical CB1/CB2 system, an expanded "endocannabinoidome" includes biochemically related mediators with their own receptors and enzymes. Clinical success has come from nabiximols (THC+CBD) for MS spasticity/pain and purified CBD for pediatric epilepsy. The endocannabinoidome is involved in multiple neurological diseases.
Key Numbers
Two cannabinoid-based medicines approved: nabiximols (THC+CBD) for MS spasticity/pain, and purified CBD for Dravet and Lennox-Gastaut syndromes. The review covers Parkinson's, Alzheimer's, Huntington's, MS, ALS, TBI, stroke, epilepsy, and glioblastoma.
How They Did This
Comprehensive review published in Nature Reviews Neurology covering the endocannabinoid system and endocannabinoidome, their involvement in neurological disorders, and current/potential therapeutic applications.
Why This Research Matters
This review from a leading neurology journal provides the most comprehensive framework for understanding how cannabinoid-based therapeutics interact with a system far more complex than originally understood.
The Bigger Picture
The discovery that the endocannabinoid system is part of a much larger "endocannabinoidome" explains both the therapeutic potential and the complexity of targeting this system pharmacologically.
What This Study Doesn't Tell Us
Review of a broad field; many therapeutic applications remain preclinical; the complexity of the endocannabinoidome makes drug development challenging.
Questions This Raises
- ?Can targeting specific endocannabinoidome components yield more precise therapies?
- ?Will understanding this expanded system explain why cannabinoid treatments have had mixed clinical results?
Trust & Context
- Key Stat:
- Two cannabinoid medicines approved: nabiximols for MS, purified CBD for epilepsy
- Evidence Grade:
- Comprehensive review in a top-tier neurology journal synthesizing extensive literature.
- Study Age:
- Published in 2020.
- Original Title:
- Cannabinoids and the expanded endocannabinoid system in neurological disorders.
- Published In:
- Nature reviews. Neurology, 16(1), 9-29 (2020)
- Authors:
- Cristino, Luigia(2), Bisogno, Tiziana(3), Di Marzo, Vincenzo(23)
- Database ID:
- RTHC-02484
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is the endocannabinoidome?
The endocannabinoidome is an expanded version of the endocannabinoid system. Beyond the classical CB1 and CB2 receptors and their endocannabinoid ligands, it includes dozens of biochemically related mediators, their own receptors, and metabolic enzymes that interact in complex ways.
Which cannabinoid-based medicines are currently approved?
As of this review, nabiximols (a THC+CBD mixture) is approved for MS spasticity and neuropathic pain, and purified cannabidiol (Epidiolex) is approved for Dravet syndrome and Lennox-Gastaut syndrome. Both have undergone rigorous clinical testing.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-02484APA
Cristino, Luigia; Bisogno, Tiziana; Di Marzo, Vincenzo. (2020). Cannabinoids and the expanded endocannabinoid system in neurological disorders.. Nature reviews. Neurology, 16(1), 9-29. https://doi.org/10.1038/s41582-019-0284-z
MLA
Cristino, Luigia, et al. "Cannabinoids and the expanded endocannabinoid system in neurological disorders.." Nature reviews. Neurology, 2020. https://doi.org/10.1038/s41582-019-0284-z
RethinkTHC
RethinkTHC Research Database. "Cannabinoids and the expanded endocannabinoid system in neur..." RTHC-02484. Retrieved from https://rethinkthc.com/research/cristino-2020-cannabinoids-and-the-expanded
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.